Benign Prostatic Hyperplasia Market expected to rise | Companies – Dongkook Pharmaceutical, Urovant Sciences, Ausio Pharmaceuticals, GlaxoSmithKline, RECORDATI GROUP, Astellas Pharma Inc

Benign Prostatic Hyperplasia Market

The Benign Prostatic Hyperplasia market growth is driven by factors like increase in the prevalence of Benign Prostatic Hyperplasia, investments in research and development, entry of emerging therapies during the study period 2019-2032.

The Benign Prostatic Hyperplasia market report also offers comprehensive insights into the Benign Prostatic Hyperplasia market size, share, Benign Prostatic Hyperplasia epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Benign Prostatic Hyperplasia market size growth forward. 

Some of the key highlights from the Benign Prostatic Hyperplasia Market Insights Report:

• Several key pharmaceutical companies, including Dongkook Pharmaceutical, Urovant Sciences, Ausio Pharmaceuticals, GlaxoSmithKline, RECORDATI GROUP, Astellas Pharma Inc, Eli Lilly and Company, Sophiris Bio Corp, Bayer, Warner Chilcott, Materia Medica Holding, Ausio Pharmaceuticals, LLC, Nymox Corporation, Olympus Medical, Butterfly Medical, SRS Medical, Teleflex Interventional Urology, Urotronic, Zenflow, ProArc Medical, Medion Biodesign, and others, are developing novel products to improve the Benign Prostatic Hyperplasia treatment outlook. 
• Promosing therapies in the Benign Prostatic Hyperplasia market are DKF0313, Vibegron, AUS-131 (S-equo), GI198745, DKF-313, Silodosin, ASP4901, Tadalafil, PRX302, Levitra (Vardenafil, BAY38-9456), WC3055, Afalaza, S-equol, NX-1207, Tamsulosin, and others.
• The total Benign Prostatic Hyperplasia market size will include the market size of the potential upcoming therapies and current treatment regimens in the seven major markets.
• As per DelveInsight analysis, the Benign Prostatic Hyperplasia market is anticipated to witness growth at a considerable CAGR
• Among the 7MM, the most prevalent cases of Benign Prostatic Hyperplasia (BPH) were recorded in the United States.
• As per a study conducted by Lim et al. (2017), the histological prevalence of Benign Prostatic Hyperplasia was observed as 8%, 50%, and 80% in the 4th, 6th, and 9th decades of life, respectively.
• A study conducted by Lee et al. (2017), titled “The global burden of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A systematic review and meta-analysis,” showed that the median point prevalence of BPH was 25.2%.
• According to the study by Lee et al., BPH is more common in older males as compared to those below 40 years. 

Strategise your business goals by understanding market dynamics @ Benign Prostatic Hyperplasia Market Landscape

Benign Prostatic Hyperplasia Overview 

Benign Prostatic Hyperplasia (BPH) refers to an enlargement of the prostate gland, while the symptoms associated with BPH are commonly known as lower urinary tract symptoms (LUTS). LUTS can manifest as irritative symptoms, obstructive symptoms, or a combination of both. Some men with BPH may not experience any symptoms, while others may find relief through lifestyle modifications, while some may require medical or surgical interventions. Symptoms of BPH typically become more prevalent as men age. These symptoms include feeling of incomplete bladder emptying, difficulty initiating urination, urinary hesitancy, weak urine flow, painful urination, frequent nighttime urination (nocturia), increased urinary frequency, and urgent need to urinate.

To diagnose BPH, the medical history of the patient is assessed, along with a physical examination that may include a digital rectal examination (DRE) and urinalysis. Additional tests such as uroflowmetry (measuring urine flow rate) and post-void residual (PVR) volume measurement may be conducted to confirm the presence of obstructive symptoms associated with BPH. There are two main classes of medications commonly used for the treatment of BPH: alpha-adrenergic blockers and 5-alpha reductase inhibitors.

Do you know the treatment paradigms for different countries? Download our Benign Prostatic Hyperplasia Market Sample Report

Benign Prostatic Hyperplasia Epidemiology Segmentation 

DelveInsight’s Benign Prostatic Hyperplasia market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Benign Prostatic Hyperplasia historical patient pools and forecasted Benign Prostatic Hyperplasia patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Benign Prostatic Hyperplasia Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:

• Benign Prostatic Hyperplasia Prevalence 
• Age-Specific Benign Prostatic Hyperplasia Prevalence 
• Gender-Specific Benign Prostatic Hyperplasia Prevalence 
• Diagnosed and Treatable Cases of Benign Prostatic Hyperplasia

Visit for more @ Benign Prostatic Hyperplasia Epidemiological Insights

Recent Breakthroughs in the Benign Prostatic Hyperplasia Market:

• Medeon Biodesign Inc., the manufacturer of the XFLO minimally invasive therapy device for Benign Prostatic Hyperplasia, announced positive results from clinical trials on January 27, 2021. The interim findings from the EXPANDER-1 clinical study were promising, and the company’s upcoming product launches are expected to contribute to market expansion.
• Olympus Corporation acquired Medi Tale Ltd., an Israeli company that produces non-surgical devices for treating Benign Prostatic Hyperplasia, on February 26, 2021. This acquisition positions Olympus as the market leader and allows the company to broaden its product range.

Benign Prostatic Hyperplasia Treatment Market 

The Benign Prostatic Hyperplasia market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Benign Prostatic Hyperplasia market trends by analyzing the impact of current Benign Prostatic Hyperplasia therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Benign Prostatic Hyperplasia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Benign Prostatic Hyperplasia market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Benign Prostatic Hyperplasia market in 7MM is expected to witness a major change in the study period 2019-2032.

Benign Prostatic Hyperplasia Therapy Assessment

Fexapotide: Nymox Pharmaceutical

Fexapotide (NX-1207) is a pro-apoptotic injectable protein and is in development for the treatment of benign prostatic hyperplasia. In February 2023, Nymox Pharmaceutical Corporation announced that the Company’s recent submission of Fexapotide Triflutate for the treatment of symptoms of benign prostate enlargement (benign prostatic hyperplasia, referred to as BPH) has been validated by the Denmark authorities, and the formal review process has now started. The trademarked name for the new product is NYMOZARFEX (TM). The Marketing Authorization Application (MAA) was submitted at the beginning of December 2022. The Company will continue to provide further information, including other expected submissions, when the information becomes available.

AIV007: AiViva BioPharma

AIV007 is a novel formulation using company’s JEL Technology designed for prolonged drug release. AIV007 targets multiple pathways including VEGFR, PDGFR, and FGFR to address neovascularization and fibrosis, and it also modulates TGFβ1 mRNA expression and TGFβ1 levels to prevent and inhibit cell proliferation. AIV007 is currently in clinical studies for neovascular macular degeneration (nAMD) treatment and in preclinical studies for Benign Prostatic Hyperplasia (BPH) (BPH), and certain solid tumors.

Benign Prostatic Hyperplasia Key Companies

• Dongkook Pharmaceutical
• Urovant Sciences
• Ausio Pharmaceuticals
• GlaxoSmithKline
• RECORDATI GROUP
• Astellas Pharma Inc
• Eli Lilly and Company
• Sophiris Bio Corp
• Bayer, Warner Chilcott
• Materia Medica Holding
• Ausio Pharmaceuticals
• Nymox Corporation
• Olympus Medical
• Butterfly Medical
• SRS Medical
• Teleflex Interventional Urology
• Urotronic
• Zenflow
• ProArc Medical
• Medion Biodesign

Benign Prostatic Hyperplasia Therapies

• DKF0313
• Vibegron
• AUS-131 (S-equo)
• GI198745
• DKF-313
• Silodosin
• ASP4901
• Tadalafil
• PRX302
• Levitra (Vardenafil, BAY38-9456)
• WC3055
• Afalaza
• S-equol
• NX-1207
• Tamsulosin

For more information, visit Benign Prostatic Hyperplasia Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Benign Prostatic Hyperplasia Market Report:

• 11 Years Forecast
• 7MM Coverage 
• Descriptive overview of Benign Prostatic Hyperplasia, causes, signs and symptoms, diagnosis, treatment
• Comprehensive insight into Benign Prostatic Hyperplasia epidemiology in the 7MM
• Benign Prostatic Hyperplasia marketed and emerging therapies 
• Benign Prostatic Hyperplasia companies
• Benign Prostatic Hyperplasia market drivers and barriers 

Key Questions Answered in the Benign Prostatic Hyperplasia Market Report 2032:

• What was the Benign Prostatic Hyperplasia market share distribution in 2019, and how would it appear in 2032?
• What is the total Benign Prostatic Hyperplasia market size and the market size by therapy across the 7MM for the study period (2019-32)?
• What are the important findings from 7MM, and which country will have the greatest Benign Prostatic Hyperplasia market size from 2019-32?
• During the study period (2019-2032), at what CAGR is the Benign Prostatic Hyperplasia market projected to expand at 7MM?

Table of Contents:

1 Benign Prostatic Hyperplasia Market Key Comprehensive Insights 

2 Benign Prostatic Hyperplasia Market Report Introduction

3 Competitive Intelligence Analysis for Benign Prostatic Hyperplasia

4 Benign Prostatic Hyperplasia Market Analysis Overview at a Glance

5 Executive Summary of Benign Prostatic Hyperplasia

6 Benign Prostatic Hyperplasia Epidemiology and Market Methodology

7 Benign Prostatic Hyperplasia Epidemiology and Patient Population

8 Benign Prostatic Hyperplasia Patient Journey

9 Benign Prostatic Hyperplasia Treatment Algorithm, Benign Prostatic Hyperplasia Current Treatment, and Medical Practices

10 Key Endpoints in Benign Prostatic Hyperplasia Clinical Trials

11 Benign Prostatic Hyperplasia Marketed Therapies 

12 Benign Prostatic Hyperplasia Emerging Therapies

13 Benign Prostatic Hyperplasia: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Benign Prostatic Hyperplasia

16 Benign Prostatic Hyperplasia Market Key Opinion Leaders Reviews

18 Benign Prostatic Hyperplasia Market Drivers

19 Benign Prostatic Hyperplasia Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Benign Prostatic Hyperplasia Epidemiology 2032

DelveInsight’s “Benign Prostatic Hyperplasia – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Benign Prostatic Hyperplasia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Benign Prostatic Hyperplasia Pipeline 2023

“Benign Prostatic Hyperplasia Pipeline Insights, 2023” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Benign Prostatic Hyperplasia market. A detailed picture of the Benign Prostatic Hyperplasia pipeline landscape is provided, which includes the disease overview and Benign Prostatic Hyperplasia treatment guidelines. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/